申请人:Novartis AG
公开号:EP2213668A2
公开(公告)日:2010-08-04
The present invention provides a compound of formula I:
said compound is inhibitor of aldosterone synthase (CYP11B2), and/or 11beta-hydroxylase (CYP11B1), and/or aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase, aromatase, or CYP11B1. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collage, fibrosis and remodeling following hypertension and endothelial dysfunction. Finally, the present invention also provides a pharmaceutical composition.
本发明提供了一种式 I 的化合物:
所述化合物是醛固酮合成酶(CYP11B2)和/或 11beta-羟化酶(CYP11B1)和/或芳香化酶的抑制剂,因此可用于治疗由醛固酮合成酶、芳香化酶或 CYP11B1 介导的紊乱或疾病。因此,式 I 化合物可用于治疗低钾血症、高血压、充血性心力衰竭、肾功能衰竭(尤其是慢性肾功能衰竭)、再狭窄、动脉粥样硬化、X 综合征、肥胖症、肾病、心肌梗塞后、冠心病、高血压后胶原形成增加、纤维化和重塑以及内皮功能障碍。最后,本发明还提供了一种药物组合物。